Health knowledge made personal
Join this community!
› Share page:
Search posts:

Immunogenic Peptides (Vaccines) for the Treatment of Prostate and Breast Cancer

Posted May 02 2012 8:00pm

Description of Invention:
Collectively, cancer is the second leading cause of death in the United States. Current treatments of cancer often involve non-specific strategies (such as chemotherapy) which attack healthy cells as well as diseased cells, leading to harmful side-effects. As a result, the development of more targeted means of treating cancer are highly sought. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of T cells that recognize the peptide. If those recognize a peptide found in a protein found selectively on cancer cells, those T cells can trigger the death of those cancer cells without harming non-cancer cells. This can result in fewer side effects for the patient. TARP (T cell receptor gamma alternate reading frame protein) is a protein that is selectively expressed on the cells of certain types of prostate and breast cancer. This invention concerns the identification of immunogenic peptides within TARP, and their use to create an anti-cancer immune response in patients. By introducing these peptides into a patient, an immune response against these cancer cells can be initiated by the peptides, resulting in treatment of the cancer. A phase I clinical trial in stage D0 prostate cancer patients is nearing completion. Initial results indicate a statistically significant decrease in the slope of PSA for 48 weeks after vaccination.

  • Peptides can be used as cancer vaccines.
  • Treatment of any cancer associated with increased or preferential expression of TARP.
  • Specific diseases include breast cancer and prostate cancer.

Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients.

Development Status:
  • Pre-clinical
  • Clinical
  • In vivo data available (animal)
  • In vivo data available (human)

Jay A Berzofsky (NCI)
Sang-kon Oh (NCI)
Ira H Pastan (NCI)

Patent Status:
HHS, Reference No. E-116-2003/0
US, , Patent No. 7,541,035, Issued 02 Jun 2009
US, , Patent No. 8,043,623, Issued 25 Oct 2011

Relevant Publication:
  1. Epel M, et al. [ PMID 18446790 ]
  2. Oh S, et al. [ PMID 15059918 ]

Collaborative Research Opportunity:
The National Cancer Institute, Vaccine Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize a prostate cancer vaccine targeting the TARP antigen currently completing phase I clinical trials. For collaboration opportunities, please contact John Hewes, Ph.D. at . Click here to view the NCI collaborative opportunity announcement.

For Licensing Information Please Contact:
David Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-4632
Fax: 301-402-0220

Ref No: 920

Updated: 05/2012

Post a comment
Write a comment:

Related Searches